Immunogenicity of a cell culture-derived inactivated vaccine against a common virulent isolate of grass carp reovirus

被引:48
|
作者
Zeng, Weiwei [1 ,2 ]
Wang, Qing [2 ]
Wang, Yingying [2 ]
Zhao, Changchen [2 ]
Li, Yingying [2 ]
Shi, Chunbin [2 ]
Wu, Shuqin [2 ]
Song, Xinjian [2 ]
Huang, Qiwen [2 ]
Li, Shoujun [1 ]
机构
[1] South China Agr Univ, Coll Vet Med, Key Lab Prevent & Control Severe Clin Anim Dis Gu, Guangzhou 510642, Guangdong, Peoples R China
[2] Chinese Acad Fishery Sci, Pearl River Fisheries Res Inst, Key Lab Fishery Drug Dev, Key Lab Aquat Anim Immune Technol,Minist Agr, Guangzhou 510380, Guangdong, Peoples R China
关键词
Inactivated vaccine; Grass carp reovirus; Humoral immune response; IMMUNE-RESPONSES; CTENOPHARYNGODON-IDELLA; VIRUS; EXPRESSION; SEQUENCE; CHINA; GCRV; GENE; PCR;
D O I
10.1016/j.fsi.2016.04.133
中图分类号
S9 [水产、渔业];
学科分类号
0908 ;
摘要
Grass carp (Ctenopharyngodon idella) hemorrhagic disease, caused by grass carp reovirus (GCRV), is emerging as a serious problem in grass carp aquaculture. There is no available antiviral therapy and vaccination is the primary method of disease control. In the present study, the immunological effects and protective efficacy of an inactivated HuNan1307 vaccine in grass carp were evaluated. The GCRV isolate HuNan1307 was produced by replication onto the grass carp PSF cell line, and inactivated with 1% beta-propiolactone for 60 h at 4 degrees C. Grass carp were injected with inactivated GCRV vaccine, followed by challenge with the isolate HuNan1307. The results showed that the minimum dosage of the inactivated vaccine was 10(5.5) TCID50/0.2 mL to induce immune protection. All grass carp immunized with the inactivated vaccine produced a high titer of serum antibodies and GCRV-specific neutralizing antibody. Moreover, the inactivated vaccine injection increased the expression of 6 immune-related genes in the spleen and head kidney, which indicated that a immune response was induced by the HuNan1307 vaccine. In addition, grass carp immunized with the inactivated vaccine showed a survival rate above 80% after the viral challenge, equal to that of grass carp immunized with a commercial attenuated vaccine, and the protection lasted at least for one year. The data in this study suggested that the inactivated HuNan1307 vaccine may represent an efficient method to induce immunity against GCRV infection and the induced disease in grass carp. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:473 / 480
页数:8
相关论文
共 43 条
  • [31] Comparison of Half and Full Doses of an MF59-Adjuvanted Cell Culture-Derived A/H1N1v Vaccine in Japanese Children
    Yasuda, Yuji
    Komatsu, Ryoya
    Matsushita, Kenji
    Minami, Taketsugu
    Suehiro, Yutaka
    Sawata, Hiroshi
    Nakura, Noriko
    Jaeger, Ralf K.
    Lattanzi, Maria
    ADVANCES IN THERAPY, 2010, 27 (07) : 444 - 457
  • [32] Immunogenicity, Safety and Reactogenicity of a Mammalian Cell-Culture-Derived Influenza Vaccine in Healthy Children and Adolescents Three to Seventeen Years of Age
    Vesikari, Timo
    Block, Stan L.
    Guerra, Fernando
    Lattanzi, Maria
    Holmes, Sandra
    Izu, Allen
    Gaitatzis, Nicolaos
    Hilbert, Anne Katrin
    Groth, Nicola
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2012, 31 (05) : 494 - 500
  • [33] Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: A sequential Phase I and Phase II clinical trial
    Groth, N.
    Montomoli, E.
    Gentile, C.
    Manini, I.
    Bugarini, R.
    Podda, A.
    VACCINE, 2009, 27 (05) : 786 - 791
  • [34] Safety and Immunogenicity of Cell Culture-Derived A/H3N2 Variant Influenza Vaccines: A Phase I Randomized, Observer-Blind, Dose-Ranging Study
    Johnson, Casey
    Hohenboken, Matthew
    Poling, Terry
    Jaehnig, Peter
    Kanesa-thasan, Niranjan
    JOURNAL OF INFECTIOUS DISEASES, 2015, 212 (01) : 72 - 80
  • [35] Safety and immunogenicity of an inactivated Vero cell_derived Japanese encephalitis vaccine (IXIARO®, JESPECT®) in a pediatric population in JE non-endemic countries: An uncontrolled, open-label phase 3 study
    Jelinek, Tomas
    Cromer, Michael A.
    Cramer, Jakob P.
    Mills, Deborah J.
    Lessans, Kenneth
    Gherardin, Anthony W.
    Barnett, Elizabeth D.
    Hagmann, Stefan H. F.
    Askling, Helena H.
    Kiermayr, Sigrid
    Kadlecek, Vera
    Eder-Lingelbach, Susanne
    Taucher, Christian
    Dubischar, Katrin L.
    TRAVEL MEDICINE AND INFECTIOUS DISEASE, 2018, 22 : 18 - 24
  • [36] Antibody responses against heterologous A/H5N1 strains for an MF59-adjuvanted cell culture-derived A/H5N1 (aH5N1c) influenza vaccine in healthy pediatric subjects
    Chanthavanich, Pornthep
    Versage, Eve
    Van Twuijver, Esther
    Hohenboken, Matthew
    VACCINE, 2021, 39 (47) : 6930 - 6935
  • [37] Antibody responses against heterologous H5N1 strains for an MF59-adjuvanted cell culture-derived H5N1 (aH5n1c) influenza vaccine in adults and older adults
    Frey, Sharon S. S.
    Versage, Eve
    Van Twuijver, Esther
    Hohenboken, Matthew
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (01)
  • [38] The novel adjuvant CoVaccineHT™ increases the immunogenicity of cell-culture derived influenza A/H5N1 vaccine and induces the maturation of murine and human dendritic cells in vitro
    Bodewes, R.
    Geelhoed-Mieras, M. M.
    Heldens, J. G. M.
    Glover, J.
    Lambrecht, B. N.
    Fouchier, R. A. M.
    Osterhaus, A. D. M. E.
    Rimmelzwaan, G. F.
    VACCINE, 2009, 27 (49) : 6833 - 6839
  • [39] Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study
    Schuller, E.
    Jilma, B.
    Voicu, V.
    Golor, G.
    Kollaritsch, H.
    Kaltenboeck, A.
    Klade, C.
    Tauber, E.
    VACCINE, 2008, 26 (34) : 4382 - 4386
  • [40] A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations
    Hatz, Christoph
    Cramer, Jakob P.
    Vertruyen, Andre
    Schwarz, Tino F.
    von Sonnenburg, Frank
    Borkowski, Astrid
    Lattanzi, Maria
    Hilbert, Anne Katrin
    Della Cioppa, Giovanni
    Leroux-Roels, Geert
    VACCINE, 2012, 30 (32) : 4820 - 4827